Milestone payment further bolsters Innate’s cash position
View post:
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
REGULATED INFORMATION
Read more from the original source:
Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that an abstract for the TRIDENT-1 clinical study of its lead drug candidate repotrectinib has been selected for a mini-oral presentation on Jan. 31, 2021 at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer.
Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF
More:
Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™
Presentations highlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections
See the original post:
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced the formation of a Scientific Advisory Board (SAB) including three of the leading global experts in exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
See the original post here:
AzurRx BioPharma Announces Formation of Scientific Advisory Board
Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/XDR Gram Negative Infections Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/XDR Gram Negative Infections
Read the original:
Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020